These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25844162)

  • 1. The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America.
    Arnold RJ; Bighash L; Bryón Nieto A; Tannus Branco de Araújo G; Gay-Molina JG; Augustovski F
    F1000Res; 2015; 4():57. PubMed ID: 25844162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A civil society view of rare disease public policy in six Latin American countries.
    Mayrides M; Ruiz de Castilla EM; Szelepski S
    Orphanet J Rare Dis; 2020 Feb; 15(1):60. PubMed ID: 32106873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact Assessment of Divergence on Post-approval Changes Classifications of Latin America Region With Europe and the United States, and Propositions to Harmonize Classification Based on Risk as a Path to Build the Trust Between National Regulatory Agencies.
    De Lucia ML; Comesaña C; Rodriguez H; Dangy-Caye A
    Clin Ther; 2024 Feb; 46(2):164-172. PubMed ID: 38092583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
    Döring JH; Lampert A; Hoffmann GF; Ries M
    PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.
    Durán CE; Cañás M; Urtasun M; Elseviers M; Vander Stichele R; Christiaens T
    PLoS One; 2021; 16(7):e0254585. PubMed ID: 34255795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars.
    Mosegui GBG; Antõnanzas F; de Mello Vianna CM; Rojas P
    Adv Rheumatol; 2021 Feb; 61(1):14. PubMed ID: 33632333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to orphan drugs - comparison across Balkan countries.
    Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
    Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
    Gammie T; Lu CY; Babar ZU
    PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of orphan drug development in Europe and the US.
    Hall AK; Carlson MR
    Intractable Rare Dis Res; 2014 Feb; 3(1):1-7. PubMed ID: 25343119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Intractable Rare Dis Res; 2012 Feb; 1(1):3-9. PubMed ID: 25343064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Practice Nursing: A Strategy for Achieving Universal Health Coverage and Universal Access to Health.
    Bryant-Lukosius D; Valaitis R; Martin-Misener R; Donald F; Peña LM; Brousseau L
    Rev Lat Am Enfermagem; 2017 Jan; 25():e2826. PubMed ID: 28146177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise of health biotechnology research in Latin America: A scientometric analysis of health biotechnology production and impact in Argentina, Brazil, Chile, Colombia, Cuba and Mexico.
    León-de la O DI; Thorsteinsdóttir H; Calderón-Salinas JV
    PLoS One; 2018; 13(2):e0191267. PubMed ID: 29415003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scorecard for osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.
    Aziziyeh R; Amin M; Habib M; Perlaza JG; McTavish RK; Lüdke A; Fernandes S; Sripada K; Cameron C
    Arch Osteoporos; 2019 Jun; 14(1):69. PubMed ID: 31250192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.